Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Table 5 Most frequent (≥5% of patients) grade 3–4 treatment-emergent adverse events (TEAEs)

Safety-evaluable patients received at least 1 dose of study drug and had at least 1 post-baseline safety assessment. Patients who received BSC only were included in safety assessments if they had at least 1 post-randomisation safety assessment
*Worsening disease

ISSN: 1471-2407